{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:06:57Z","timestamp":1789243617340,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["CB16\/12\/00328"],"award-info":[{"award-number":["CB16\/12\/00328"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","award":["SGR 2021 01157"],"award-info":[{"award-number":["SGR 2021 01157"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119830","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:24:57Z","timestamp":1785839097000},"page":"119830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2\/neu expressing endometrial cancer"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-0184","authenticated-orcid":false,"given":"Cristian Pablo","family":"Moiola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lopez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rebull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sotoca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"De la Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-2535","authenticated-orcid":false,"given":"Melek","family":"Denizli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-9707","authenticated-orcid":false,"given":"Lourdes","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"van der Vleuten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Bebia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4574-0582","authenticated-orcid":false,"given":"Valeria","family":"Tubita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Groothuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0302-4828","authenticated-orcid":false,"given":"Eva","family":"Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119830_bib1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119830_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2026.119830_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119830_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/ijgc-2020-002256","article-title":"p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","volume":"31","author":"Jamieson","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2026.119830_bib5","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.3390\/cancers15215123","article-title":"Optimal management for stage IVB endometrial cancer: a systematic review","volume":"15","author":"Capozzi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119830_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.biopha.2026.119830_bib7","series-title":"Biomark Cancer [Internet]","first-page":"1","article-title":"HER2 as biomarker for endometrial cancer","author":"English","year":"2014"},{"key":"10.1016\/j.biopha.2026.119830_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2015.01.533","article-title":"HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant","volume":"137","author":"Growdon","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biopha.2026.119830_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ygyno.2025.10.025","article-title":"Corrigendum to \u201cHER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study\u201d [Gynecologic Oncology 194 (2025) 33\u201340","volume":"203","author":"Cort\u00e9s-Salgado","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44276-025-00125-6","article-title":"HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups","volume":"3","author":"Aro","year":"2025","journal-title":"BJC Rep."},{"key":"10.1016\/j.biopha.2026.119830_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","article-title":"HER2-positive gastric cancer","volume":"17","author":"Boku","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.biopha.2026.119830_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the Treatment of Breast Cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2026.119830_bib16","first-page":"15","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010"},{"key":"10.1016\/j.biopha.2026.119830_bib17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1634\/theoncologist.2015-0149","article-title":"The therapeutic challenge of targeting HER2 in endometrial cancer","volume":"20","author":"Diver","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2026.119830_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12672-026-04492-5","article-title":"Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics","volume":"17","author":"Rejili","year":"2026","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cancers16040800","article-title":"Next-generation HER2-targeted antibody\u2013drug conjugates in breast cancer","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119830_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol. Am. Soc. Clin. Oncol. (ASCO)"},{"key":"10.1016\/j.biopha.2026.119830_bib21","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119830_bib22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody\u2013drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119830_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2026.119830_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/ph14050442","article-title":"The chemistry behind ADCs","volume":"14","author":"Kostova","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119830_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","article-title":"The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers","volume":"14","author":"Van Der Lee","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119830_bib26","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/j.annonc.2024.08.797","article-title":"735P HRD signature (HRDsig) in endometrial cancer (EC)","volume":"35","author":"Pothuri","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241298329","article-title":"Update on combination strategies of PARP Inhibitors","volume":"31","author":"Lin","year":"2024","journal-title":"Cancer Control."},{"key":"10.1016\/j.biopha.2026.119830_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41698-026-01347-8","article-title":"HRD in endometrial cancer: LST loss drives distinct genomic profile and platinum response","volume":"10","author":"Wan","year":"2026","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153032","article-title":"ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer","volume":"216","author":"Sun","year":"2020","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.biopha.2026.119830_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/OTT.S426923","article-title":"Inhibition of ATM with KU-55933 sensitizes endometrial cancer cell lines to Olaparib","volume":"16","author":"Zhang","year":"2023","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.biopha.2026.119830_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102859","article-title":"Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings","volume":"36","author":"Willman","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2026.119830_bib32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-023-37084-w","article-title":"Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma","volume":"14","author":"Madariaga","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119830_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2022.05.021","article-title":"Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2\/neu","volume":"166","author":"Yadav","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cXenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119830_bib36","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"DeRose","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119830_bib37","article-title":"A Validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma","volume":"4","author":"Sivanand","year":"2012","journal-title":"Sci. Transl. Med. [Internet]"},{"key":"10.1016\/j.biopha.2026.119830_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-Derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119830_bib39","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.1038\/ncomms9305","article-title":"Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers","volume":"6","author":"Misale","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119830_bib40","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/1078-0432.CCR-17-0615","article-title":"A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1\/2 wild-type tumors","volume":"23","author":"Evans","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119830_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molonc.2014.01.008","article-title":"Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts","volume":"8","author":"Topp","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib42","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/0008-5472.CAN-14-1590","article-title":"Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data","volume":"75","author":"Nunes","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119830_bib43","article-title":"Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts","volume":"114","author":"Fior","year":"2017","journal-title":"Proc. Natl. Acad. Sci. [Internet]"},{"key":"10.1016\/j.biopha.2026.119830_bib44","article-title":"A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers","volume":"2","author":"George","year":"2017","journal-title":"JCI Insight [Internet]"},{"issue":"8","key":"10.1016\/j.biopha.2026.119830_bib45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrclinonc.2015.62","article-title":"Mouse hospital and co-clinical trial project\u2014from bench to bedside","volume":"12","author":"Clohessy","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s43856-021-00019-x","article-title":"Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis","volume":"1","author":"Berg","year":"2021","journal-title":"Commun. Med."},{"key":"10.1016\/j.biopha.2026.119830_bib47","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.3390\/ijms23116266","article-title":"Genomic validation of endometrial cancer patient-derived xenograft models as a preclinical tool","volume":"23","author":"Villafranca-Magdalena","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119830_bib48","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.cell.2026.03.035","article-title":"Targeting genomic instability in cancer","volume":"189","author":"Yap","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119830_bib49","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib50","first-page":"40","article-title":"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"192","author":"Powell","year":"2025"},{"key":"10.1016\/j.biopha.2026.119830_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119830_bib53","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/mc.23064","article-title":"Activation of Wnt signaling promotes olaparib resistant ovarian cancer","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.biopha.2026.119830_bib54","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119830_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-021-00990-z","article-title":"Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer","volume":"14","author":"Bonazzi","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.biopha.2026.119830_bib56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12943-026-02594-w","article-title":"Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs","volume":"25","author":"Jian","year":"2026","journal-title":"Mol. Cancer"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:41:02Z","timestamp":1789242062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S0753332226008668"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119830","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2\/neu expressing endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119830"}}